JERSEY CITY, NJ, August 3, 2017 – TrialScope, a global clinical trial transparency and compliance solutions company, announced the launch of its newest solution, Core Disclosure. It enables teams to approve disclosure content once and then reuse the disclosure data around the globe.
Core Disclosure addresses the need to streamline the disclosure process and remove wasted time and resources.
The solution works to:
“Core Disclosure is a market-driven solution that was developed in consultation with our community of disclosure professionals,” said Mark Heinold, TrialScope’s Chief Executive Officer. “As trial disclosure regulations increase, we are thrilled to offer sponsors a solution to streamline the process, allowing them to put the focus back on their trial.”
Core Disclosure, which can be purchased as a standalone solution, was designed to integrate with TrialScope’s other suite of offerings, including ATLAS and PharmaCM.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.